adults age≥65 with back pain, osteoarthritis or rheumatoid arthritis and minimum of 12-months medical and drug plan enrollment. Members were mailed a survey in May 2018 assessing positive resources, negative attributes and pain outcomes of pain. Opioid and other medications were determined from drug claims. The population was propensity weighted to adjust for survey non-response bias; weighted to generalize to those with diagnosed pain. Multivariate logistic regression was used to determine protective associations of positive resources with negative attributes on outcomes. Among respondents, 30% were internal LOC; 34% powerful other; 36% chance. In multivariate models, demographics, socioeconomics, health status, pain medications, resilience and social network, internal LOC was associated with lower pain severity, reduced opioid use and increased physical function. Magnitude of impact was comparable to resilience and diverse social networks. Powerful other LOC was partially protective with improved psychosocial attributes but poorer pain outcomes; chance LOC was associated with poor psychosocial/pain outcomes. Despite positive resources, depression and poor sleep maintained associations with pain outcomes. Internal LOC is a strong positive resource associated with improved pain. Multidimensional programs should include enhancing positive resources, including LOC, and focus on improving negative attributes to maximize pain management. Medicine, Miami, Florida, United States, 3. Miami VA GRECC, Miami, Florida, United States Hypoglycemia evaluation is expected in every encounter with diabetic patients. However, self-monitoring and self-management may not be complete at home, and limited by geriatric syndromes. Furthermore, hypoglycemia risk increases with age, and rurality may limit access to frequent monitoring. We identified 112 rural veterans with high hypoglycemia risk, using the local medication database (sulfonylureas and insulin), combined with age and glycated hemoglobin (HbA1c). Statistical analyses were conduct using SAS 9.4 (Cary, NC). We used Chi-square, Fisher's, One-way ANOVA for baseline variables, and a multivariate logistic regression model to assess the association of hypoglycemia and risk factors, including age, HbA1c%, self-monitoring, and knowledge. Hypoglycemia was reported in 30.4% of cases, of whom the majority were younger than those not reporting hypoglycemia (72.0±4.3 vs 75.0±6.5 years, p=.015). Baseline HbA1c% was higher in cases with hypoglycemia compared to those without (7.7±1.6% versus 7.3±1.2%, not statistically significant). There were no significant differences between pharmacologic regimens, self-monitoring, and general knowledge. Veterans who knew hypoglycemia symptoms were 6 times more likely to reported hypoglycemia, compared with veterans who did not know any symptoms. We contacted primary care teams (PCT) for whom medications were adjusted. Hypoglycemia risk is high in the older population, and telemedicine programs can support primary care teams to improve management of their patients. Poor symptom knowledge needs to be addressed, while considering special attention for hypoglycemia unawareness in the oldest age group. We are implementing a project using continuous glucose monitoring in this high-risk population. With more than 500,000 patients with Alzheimer's disease, constituting nearly 10% of all cases in the US, the state of Florida spends an estimated $20 billion per year on care and treatment related to this disease. The Florida State Plan on Aging reported that 75% of informal caregivers felt that early education and training should be a high priority for the state, and that difficult behaviors and limited knowledge about dementias were among the most significant challenges that they faced. The REACH II intervention is the goldstandard for evidence-based practices that address burden, well-being, and skills training for dementia caregivers. This presentation describes the partnership of a Memory Disorder Clinic (MDC) team and two university-based researchers working to embed a modified REACH protocol into an outpatient clinic. Critical streamlined components and new material designed to innovations since the REACH trials. The FL-REACH protocol is significantly shorter, adds a structured assessment for both patient and family needs, expands to include advanced care planning and grief modules, and intentionally builds linkages to the medical care team, with a focus on outreach to diverse families. This manualized intervention is offered to families of patients diagnosed through the MDC, thus capitalizing on the rapport and trust that is built, and providing in-house opportunities to engage diverse populations with a program grounded in the evidence base. This intervention provides critical foundational training for families that will bridge to seamless team coordination in the future. SA has been reported four times more often as compared to other non-veteran cohorts. (Wong 2015) . The risk of developing dementia is increased in older individuals with OSA (Shastri, Bangar, & Holmes, 2015) . The prevalence and characteristics of older adults with dementia and sleep apnea is not well known and long-term population-based studies on mortality have been lacking. Recent studies have reported overall mortality rates of 19%, in those individuals with SA, an increased rate of 1.5-3 times the mortality rate as compared to those individuals those without SA. Current recommendations support SA screening of high risk individuals including those with symptoms of snoring, fatigue, memory and concentration problems and mood changes. (Krist 2018) . Despite a large number of older adults with suspected SA and comorbidities, the majority are not screened, referred, diagnosed and treated. In this VA pilot study of outpatient older male veterans with dementia and SA, N=195, mean age 75.83 years, SD=9.1, 51.3% were white, 37.5% were black. Frequently found comorbidities were: hypertension 88%, congestive heart failure 41%, Diabetes. 62% and, stroke 21%. Of note, among those who died, SA was significantly related to congested heart failure (r=.32, p<.001) and COPD (r=.40, p<.001). The overall mortality rate of 27% was higher than previous reports. Further investigation is needed to better understand the relationship between comorbidities, and SA, screening, treatment and mortality. Five randomized, double-masked, placebo-controlled trials were conducted in the US in adults with DED, an eye dryness score (EDS, visual analogue scale [VAS], 0-100) ≥40, and inferior corneal staining score ([ICSS], 0-4) ≥2.0 at study entry: four 84-day efficacy trials (phase 2, lifitegrast n=58, placebo, n=58; phase 3: OPUS-1, n=293, n=295; OPUS-2, n=358, n=360; OPUS-3, n=355, n=356) and a 1-year safety study (SONATA, lifitegrast n=220, placebo n=111). The pooled population had a mean age of 59.4 years, and 76% were females. Lifitegrast treatment, versus placebo, significantly improved EDS from baseline to day 84 in three of the four trials: OPUS-1 (treatment effect [TE] 4.7; P=0.0311), OPUS-2 (TE 12.3; P<0.0001), and OPUS-3 (TE 7.5; P=0.0003). Lifitegrast significantly improved ICSS in the phase 2 (TE 0.25; P=0.0498) and OPUS-1 (TE 0.23; P=0.0007) trials, and nominally in OPUS-3 (TE 0.17; nominal P=0.0135). The responder analyses from OPUS-2 and OPUS-3 assessed the proportion of subjects with an EDS reduction from baseline (≥10, ≥15, ≥20 points), and percentage change from baseline (≥30, ≥50, ≥70%), to days 14, 42 and 84. More subjects achieved ≥30% EDS reduction with lifitegrast versus placebo in Opus-2, and Opus 3 at days 14, 42, and 84 (all nominal P<0.0001). A similar trend was seen at other response thresholds. Pooled safety data (lifitegrast n=1287; placebo, n=1177) indicated Lifitegrast was well tolerated with no serious ocular adverse events. Lifitegrast significantly improved signs and symptoms of DED in adult subjects, with EDS improvements observed starting at day 14 after treatment. Dyspnea is the primary and most disabling symptoms seen in chronic obstructive pulmonary disease (COPD). Primary pathophysiological changes such as dynamic hyperinflation have been associated with the etiology of dyspnea in chronic obstructive pulmonary disease (COPD). However, since the experience of dyspnea "derives from interactions among multiple physiological, psychosocial and environmental factors", a single correlate to accurately predict dyspnea has not been established. The purpose of this study was to identify factors that could predict shortness of breath during stair climb (SOB-SC) in community dwelling adults with COPD. We hypothesized that physical activity and muscle strength would significantly predict SOB-SC. Individuals with COPD who participated in the National Health and Nutrition Examination Survey (NHANES) between years 1999-2002 were selected for this study. Participants were excluded if they had significant mobility limitations. Socioeconomic, demographic variables, and clinical variables including BMI, physical activity, comorbidities, muscle strength, ankle brachial index, waist circumference and inflammatory markers were extracted. Logistic regression models were plotted with SOB-SC as the categorical dependent variable after assessing for collinearity using the forced-entry method. Individuals with COPD had a significantly greater proportion of SOB-SC (χ = 134.87, p < 0.001). Larger waist circumference (p = 0.002, CI = 0.04 -0.13), presence of cardiovascular disease (p = 0.001, CI = 0.76 -2.37) and Caucasian race were found to significantly predict SOB-SC after controlling for covariates. This study reinforces the importance of screening for cardiovascular disease and lifestyle modification in this population subgroup. Future studies examining differences in COPD severity are needed.
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